News

This is the first international Chemistry, Manufacturing and Controls (CMC) development and manufacturing project empowered by the Oncolytic Virus contract development and manufacturing organization (CDMO) platform, which has

The new facility also facilitates the production of advanced and difficult-to-manufacture solid dosage forms such as tablets and capsules, in addition to the manufacturing of novel CAR-T cell

“There are no FDA-approved treatments currently available to patients diagnosed with molluscum, the majority of whom are children, leaving caregivers to choose between a wait-and-see approach or treatments

“Today’s submission represents a significant step forward for Evofem and for the millions of women who are dissatisfied with their current contraceptive options and are eagerly awaiting a

The NDA has been accepted for the priority review of selective fibroblast growth factor receptor (FGFR) inhibitor pemigatinib to treat patients with previously treated, locally advanced or metastatic

Under the terms of the collaboration, Lonza will provide DiNAQOR preclinical, clinical and commercial production support for the company’s lead preclinical program DiNA-001, an adeno-associated virus (AAV) gene therapy program

Oxbryta, an oral therapy taken once daily, is the first approved treatment that directly inhibits sickle hemoglobin polymerization, the root cause of SCD.2,3 The medicine is expected to

The Japanese conglomerate plans to acquire Veloxis Pharmaceuticals through its Danish subsidiary Asahi Kasei Pharma Denmark in a move to accelerate its transformation into a global healthcare company.

In this connection, Ferring Pharmaceuticals has launched a new company FerGene, which will focus on the global development and US commercialisation of nadofaragene firadenovec. The gene therapy is